Longeveron

Miami, United States Founded: 2014 • Age: 12 yrs Listed
Cellular therapies for aging-related and life-threatening conditions are developed.

About Longeveron

Longeveron is a publicly listed company based in Miami (United States) founded in 2014 by Joshua M Hare. Cellular therapies for aging-related and life-threatening conditions are developed. Longeveron has raised $1.05 million across 9 funding rounds from investors including NIH, HHS and TEDCO. The company has 26 employees. Longeveron offers products and services including Lomecel-B. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Drugs and Neurology. Its legal entity is LONGEVERON INC. Its competitors include T3D Therapeutics, Alzheon and Totus Medicines; 3 of its 3 listed competitors have raised funding.

Company details

Longeveron was founded in 2014 in Miami, United States, within the biotechnology sector focused on cellular therapies. Operations center on the development of treatments derived from culture-expanded medicinal signaling cells sourced from adult human bone marrow donors. The lead candidate, Lomecel-B, is targeted at conditions including aging frailty, Alzheimers disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome.

  • Headquarters Miami, United States
  • Employees 26
  • Founders Joshua M Hare
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website longeveron.com
  • Social LinkedIn Instagram YouTube
  • Legal Name Longeveron Inc.
Key Metrics
  • Annual Revenue
    $1.2 M (USD)
    -49.87
    as on Dec 31, 2025
  • Net Profit
    -$22.7 M (USD)
    -42.14
    as on Dec 31, 2025
  • EBITDA
    -$22.06 M (USD)
    -41.75
    as on Dec 31, 2025
  • Total Equity Funding
    $1.05M (USD)

    in 9 rounds

  • Latest Funding Round
    $15M (USD), Post-IPO

    Mar 2026

  • Investors
    NIH

    & 7 more

  • Employee Count
    26

Products & Services of Longeveron

Longeveron offers a comprehensive portfolio of products and services, including Lomecel-B.

Lomecel-B
Cellular Therapy

Stem cell-based treatment for heart and neurodegenerative diseases

Apps and channels of Longeveron

its YouTube channel Benzinga Events has 3.41K subscribers and 30 videos.

Benzinga Events
YouTube 3.41K subscribers 30 videos Travel & Events
Open channel

Videos from Longeveron

The most watched videos on Longeveron's YouTube channel, Benzinga Events (3.41K subscribers). Click a video to play it here.

Exclusive Insights from For BullRush | Benzinga's Fintech & FODA Event
132 views
Exclusive Insights from iTrustCapital | Benzinga's Fintech & FODA Event
120 views
Exclusive Insights from Sequentum Inc. | Benzinga's Fintech & FODA Event
108 views
Exclusive Insights from Aspida | Benzinga's Fintech & FODA Event
89 views

More on Benzinga Events.

Funding Insights of Longeveron

Longeveron has successfully raised a total of $1.05M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $15 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $1.05M
  • Total Rounds 9
  • Last Round Post-IPO β€” $15M
  • First Round $750,000

    (May 2017)

  • Investors Count 8

All 9 funding rounds of Longeveron with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2026$15MPost-IPO––
Dec 2021$20.46MPost-IPO––
–
Feb 2020$100,000Seed––
–
Nov 2018$6.7MGrant––
Oct 2018$3.8MGrant––
Sep 2018$4.24MGrant––
Oct 2017$954,970Seed––
–
Sep 2017$1.05MGrant––
May 2017$750,000Grant––
Valuation history

8 investors in total: 8 institutional.

Investors in Longeveron

Longeveron has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, HHS and TEDCO.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Venture capital fund and startup accelerator programs focused on seed and early stage companies
1998tedcomd.comColumbia, United States
Stem cell research startups in healthcare are funded and accelerated.
mscrf.orgColumbia, United States
janushenderson.com
logoscapital.com
Drug discovery services are provided to the biopharma sector.
1887nih.govUnited States
Public health and human services are overseen by HHS.
1953hhs.gov
coastlandscapital.com
kalehuacapital.com
Premium access

Investor details for Longeveron

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Longeveron

25 people are tracked at Longeveron (7 in leadership, 12 in board & advisors, 6 in team); the tracked headcount is 26.

NameRoleGroup
Joshua M Hare
Co-FounderLeadership
Wa'el Hashad
CEOLeadership
Lisa McClain-Moss
VP, ManufacturingLeadership
Heather Zhou
Vice President & Corporate ControllerLeadership
Lisa Locklear
CFOLeadership
Nataliya Agafonova
Chief Medical OfficerLeadership
Jen Dumas
Vice President, Human ResourcesLeadership
Jeffrey Pfeffer
DirectorBoard & advisors
Khoso Baluch
DirectorBoard & advisors
Erin Borger
DirectorBoard & advisors
Hidenori Arai
AdvisorBoard & advisors
Elena Volpi
AdvisorBoard & advisors
Ursula Ungaro
DirectorBoard & advisors
Douglas Losordo
DirectorBoard & advisors
Jeremy D. Walston
AdvisorBoard & advisors
Donald M. Soffer
DirectorBoard & advisors
Cathy Ross
DirectorBoard & advisors
Joe G. N. Garcia
AdvisorBoard & advisors
Rock Soffer
DirectorBoard & advisors
Michael Brown
Senior Manufacturing Associate & Team LeadTeam

5 more people are available in the full profile.

Premium access

Complete people profiles for Longeveron

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Longeveron

Longeveron is a publicly listed company on the NASDAQ with ticker symbol LGVN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date12 Feb 2021
  • Listed onNASDAQ: LGVN
  • Listed entityLongeveron Inc.
  • Exchange sectorHealth technology
  • ISINUS54303L3024
  • Share price$2.15 (-12.24% on the day) · 2026-10-13
  • Market capitalisation$6.9M
  • EPS (diluted, trailing year)$-10.15
  • Volume (last session)60,522

Financials of Longeveron

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$1.2M-$22.7M-$22.1M
2024$2.4M-$16.0M-$15.6M
2023$709,000-$21.4M-$19.7M
2022$1.2M-$18.8M-$17.1M
2021$1.3M-$17.1M-$16.5M
Premium access

Detailed financial statements for Longeveron

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Longeveron

4 dated milestones of Longeveron across 12 years, from founding to its latest funding, stage changes and deals.

  1. Founded Longeveron is founded.
  2. Funding First funding round of $750K.
  3. IPO Lists on the stock exchange (IPO).
  4. Funding Latest funding round, Post-IPO, of $15.0M.

Competitors of Longeveron

Longeveron has 3 listed competitors in our database, 3 of them funded. They include T3D Therapeutics, Alzheon and Totus Medicines.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
t3dtherapeutics.com2013Durham, United States$33.02M
Therapeutics for neurodegenerative diseases, including Alzheimer's, are developed.
alzheon.com2013Framingham, United States$195.25M
Oral inhibitors of amyloid aggregation for Alzheimer's treatment are developed.
totusmedicines.com2019Cambridge, United States$106M23
Genome-scale drug discovery platform is provided for treating multiple diseases.
Premium access

Detailed competitors of Longeveron

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Longeveron

The website of Longeveron (longeveron.com) receives about 3.1K visits a month and ranks #3,823,999 among all websites worldwide, #4,881 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    3.1K

    ▼ 43.5% vs previous month

  • Unique visitors
    2.1K

    per month

  • Global rank
    #3,823,999

    among all websites

  • Category rank
    #4,881

    Health · Biotechnology and Pharmaceuticals

Top companies in Pulmonology

3 companies that operate in the same segment as Longeveron (Pulmonology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of novel protein-based therapeutics using machine learning and biological engineering
2018Somerville, Massachusetts, United StatesUSD 693 M329
Portable oxygen concentrators are supplied for respiratory therapy needs.
2001Goleta, California, United StatesUSD 51.65 MUSD 348.67 M766
Robotic microsurgical systems for endoscopy are developed.
2007Redwood City, California, United StatesUSD 733.62 M91
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Longeveron

Premium access

Complete news archive for Longeveron

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Longeveron

Longeveron was founded in 2014 and raised its 1st funding round 3 years after it was founded.

Longeveron is headquartered in Miami, United States. It is registered at Miami, Florida, United States.

Longeveron is a funded company, having raised a total of $1.05M across 9 funding rounds to date. The company's 1st funding round was a Grant of $750K, raised on May 2017.

Longeveron has 26 employees.

Annual revenue of Longeveron is $1.2M as on Dec 31, 2025.

Longeveron was founded in 2014 in Miami, United States, within the biotechnology sector focused on cellular therapies. Operations center on the development of treatments derived from culture-expanded medicinal signaling cells sourced from adult human bone marrow donors. The lead candidate, Lomecel-B, is targeted at conditions including aging frailty, Alzheimers disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome.

Longeveron's top competitors include Alzheon, Totus Medicines and T3D Therapeutics.

Longeveron offers Lomecel-B.

Yes, Longeveron is publicly traded on NASDAQ under the ticker symbol LGVN.

Longeveron has 8 investors. Key investors include NIH, HHS, TEDCO, Maryland Stem Cell Research Fund, and Coastlands Capital.

Longeveron operates through Longeveron Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available